India, July 9 -- Last month the U.S. Food and Drug Administration (FDA) had approved the CAPVAXIVE vaccine for pneumococcal infections in at-risk children aged 2 years or older. However, recent confusion in authorization committees within the U.S. Health Department may impede distribution of the vaccine.
CAPVAXIVE is a 21-valent conjugate vaccine acting against various strains of Streptococcus pneumoniae, that first received FDA approval on June 17, 2024, for the prevention of pneumonia in patients aged 18 or older. The vaccine is indicated for individuals at higher risk to acquire S. pneumoniae infections, potentially leading to pneumonia, meningitis, or bacteremia.
Developed and marketed by Merck and Dohme LLC, the single-shot vaccine i...